Robert W. Peabody
Chief Operating Officer at ES Cell International Pte Ltd.
Profile
Robert W.
Peabody is currently a Director at Cell Cure Neurosciences Ltd., Chief Operating Officer & Director at ES Cell International Pte Ltd., and Secretary at OrthoCyte Corp.
Previously, he held positions as Chief Financial Officer & Director at Asterias Biotherapeutics, Inc., Chief Operating Officer, Director & Senior VP at OncoCyte Corp., Regional Controller at Ecolab, Inc., Chief Financial Officer & Senior Vice President at Lineage Cell Therapeutics, Inc., Audit Manager at Ernst & Young LLP, Principal at The ACT Group, Inc., and Vice President-Grant Administration at Astellas Institute for Regenerative Medicine.
He obtained his undergraduate degree from the University of Michigan.
Robert W. Peabody active positions
Companies | Position | Start |
---|---|---|
ES Cell International Pte Ltd.
ES Cell International Pte Ltd. BiotechnologyHealth Technology ES Cell International Pte Ltd. develops human embroyonic stem cell technologies for research and commercial applications. It develops an array of intellectual property in the fields of drug discovery, diagnostics, and therapeutics based on stem cell technology. The company was founded by Ariff Bongso, Robert Klupacs, Martin F. Pera, Reubinoff Benjamin and Alan Osborne Trounson in 2000 and is headquartered in Singapore. | Chief Operating Officer | 26/07/2011 |
OrthoCyte Corp.
OrthoCyte Corp. Pharmaceuticals: MajorHealth Technology Part of Lineage Cell Therapeutics, Inc., OrthoCyte Corp. develops cellular therapeutics for orthopedic repair diseases and injuries. The company is based in Alameda, CA. The CEO of the company is Michael D. West. | Corporate Secretary | - |
Cell Cure Neurosciences Ltd.
Cell Cure Neurosciences Ltd. BiotechnologyHealth Technology Cell Cure Neurosciences Ltd. develops cell therapies for neural degenerative diseases. Its therapeutic cells include retinal pigmented epithelial (RPE) cells and neural progenitor cells. The firm's cells are derived from human embryonic stem cells (hESCs), which are considered to be the gold standard source of cells for the development of stem cell therapies. The company was founded in 2005 and is headquartered in Jerusalem, Israel. | Director/Board Member | - |
Former positions of Robert W. Peabody
Companies | Position | End |
---|---|---|
LINEAGE CELL THERAPEUTICS, INC. | Director of Finance/CFO | 15/11/2015 |
OCATA THERAPEUTICS INC | Corporate Officer/Principal | 13/09/2007 |
ONCOCYTE CORPORATION | Director of Finance/CFO | - |
ASTERIAS BIOTHERAPEUTICS INC | Director of Finance/CFO | 08/11/2015 |
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Comptroller/Controller/Auditor | 02/05/2011 |
Training of Robert W. Peabody
University of Michigan | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 3 |
---|---|
ECOLAB INC. | Process Industries |
LINEAGE CELL THERAPEUTICS, INC. | Health Technology |
ONCOCYTE CORPORATION | Health Technology |
Private companies | 6 |
---|---|
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Commercial Services |
Astellas Institute for Regenerative Medicine
Astellas Institute for Regenerative Medicine Pharmaceuticals: MajorHealth Technology Astellas Institute for Regenerative Medicine engages in the development and commercialization of human pluripotent stem cell technology in the field of regenerative medicine. The company also have a preclinical development pipeline in areas outside of ophthalmology, including; autoimmune diseases, inflammatory diseases, and wound healing. The company was founded on May 18, 2000 and is headquartered in Marlborough, MA. | Health Technology |
ES Cell International Pte Ltd.
ES Cell International Pte Ltd. BiotechnologyHealth Technology ES Cell International Pte Ltd. develops human embroyonic stem cell technologies for research and commercial applications. It develops an array of intellectual property in the fields of drug discovery, diagnostics, and therapeutics based on stem cell technology. The company was founded by Ariff Bongso, Robert Klupacs, Martin F. Pera, Reubinoff Benjamin and Alan Osborne Trounson in 2000 and is headquartered in Singapore. | Health Technology |
OrthoCyte Corp.
OrthoCyte Corp. Pharmaceuticals: MajorHealth Technology Part of Lineage Cell Therapeutics, Inc., OrthoCyte Corp. develops cellular therapeutics for orthopedic repair diseases and injuries. The company is based in Alameda, CA. The CEO of the company is Michael D. West. | Health Technology |
Asterias Biotherapeutics, Inc.
Asterias Biotherapeutics, Inc. BiotechnologyHealth Technology Asterias Biotherapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing and commercializing novel therapies in the emerging fields of cell therapy and regenerative medicine. Its product candidates include AST-OPC1, trial for spinal cord injuries; AST-VAC1, a patient specific cancer immunotherapy focused on acute myeloid leukemia; and AST-VAC2, a non-patient-specific cancer immunotherapy for non-small cell lung cancer. The company was founded on September 24, 2012 and is headquartered in Fremont, CA. | Health Technology |
Cell Cure Neurosciences Ltd.
Cell Cure Neurosciences Ltd. BiotechnologyHealth Technology Cell Cure Neurosciences Ltd. develops cell therapies for neural degenerative diseases. Its therapeutic cells include retinal pigmented epithelial (RPE) cells and neural progenitor cells. The firm's cells are derived from human embryonic stem cells (hESCs), which are considered to be the gold standard source of cells for the development of stem cell therapies. The company was founded in 2005 and is headquartered in Jerusalem, Israel. | Health Technology |
- Stock Market
- Insiders
- Robert W. Peabody